Drug intelligence / Profile preview

NTX-05

Development stage: Preclinical
Lead developer: Next Innovative Therapeutics

Overview

NTX-05 is a preclinical-stage drug candidate being developed by Next Innovative Therapeutics (NInTx) for immuno-oncology applications. Discovered through NInTx's proprietary platforms (such as GAIApath and xGIbiomics) which leverage Brazilian biodiversity, NTX-05 is designed as an immune checkpoint sensitizer. It functions by sensitizing tumors or the immune system to immune checkpoint activity, thereby enhancing the efficacy of checkpoint-based immunotherapies.

Targets

Checkpoint (Immune checkpoints)

Beyond the preview

Go deeper on NTX-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-05.